Tier 3 — preclinical

Protective Roles of Apigenin Against Cardiometabolic Diseases: A Systematic Review

Yajie Xu, Xue Li, Hui Wang
Frontiers in Nutrition 2022 9:875826

Bibliography

PubMed
PMID 35495935
PubMed Central
PMC9051485
DOI
10.3389/fnut.2022.875826
Funding
Supported by Chinese public research funding including National Natural Science Foundation of China grants 81803215 and 81630086 and Shanghai research support.
Competing interests
The authors declared that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignSystematic review of apigenin in cardiometabolic disease models
ModelPublished cell and animal models of obesity, diabetes, hypertension and cardiovascular disease
SampleMultiple preclinical studies; no pooled human intervention population.
InterventionApigenin and selected apigenin analogs across cardiometabolic experimental models.
DurationVaried across included studies.
EndpointsObesity and lipid metabolism; Glucose homeostasis and insulin signaling; Endothelial function; Blood pressure and renal fibrosis; Cardiac hypertrophy; AMPK, PPAR, Nrf2 and PI3K/AKT pathways

What the study showed, in plain terms

This systematic review collects experimental research on apigenin in obesity, diabetes, hypertension and cardiovascular disease. It identifies several plausible metabolic and vascular pathways, but the evidence reviewed is mainly cell and animal work rather than clinical trials of apigenin in people.

Key findings

Across preclinical models, apigenin influenced adipogenesis, lipid oxidation, hepatic metabolism, glucose handling, oxidative stress, endothelial signaling and cardiac remodeling. AMPK/PPAR, Nrf2, PI3K/AKT and related pathways recur across the literature.

What this study can and cannot tell us

The review is mechanistic and preclinical. Study designs, doses, routes and disease models vary, and benefits in rodents or cultured cells cannot establish prevention or treatment of cardiometabolic disease in humans.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology